Pyrimidine nucleobase biosynthetic process

Across TCGA pan-cancer cohorts, RNA activity of the Pyrimidine nucleobase biosynthetic process pathway is associated with patient survival in 20 of 34 cancer lineages. Pathway activity is summarized from the expression of its 8 member genes.

The strongest signal is observed in mesothelioma (MESO), where higher Pyrimidine nucleobase biosynthetic process pathway activity is associated with better overall survival. In most high-consensus cancer types, elevated pathway activity shows an unfavorable survival association, although some cancer types, such as MESO and SCLC, show the opposite pattern, with higher activity associated with better survival.

MESO, SCLC, and THYM are the cancer lineages in which this pathway most reproducibly stratifies patient survival.

Pathway-activity survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 represent the survival AUCs for the high- and low-pathway-activity groups, respectively. The group with the lower AUC is interpreted as having poorer survival. The reported p-values are derived from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.674	0.416	<.001	105	view →
SCLC	OS	Median	II,III,IV	0.628	0.233	<.001	62	view →
THYM	DFS	Tertile	All	1.000	0.545	<.001	53	view →
SARC	OS	Median	All	0.397	0.586	<.001	28	view →
THCA	DFS	Median	IV	0.602	0.878	.004	27	view →
BRCA	DFS	Median	II,III,IV	0.859	0.912	.018	20	view →
LGG	DFS	Tertile	All	0.312	0.478	<.001	20	view →
KIRC	OS	Median	All	0.835	0.897	.024	16	view →
ACC	OS	Quartile	IV	0.296	0.772	.008	15	view →
LUSC	OS	Quartile	All	0.752	0.558	.005	13	view →
READ	OS	Median	III,IV	0.744	0.984	.002	9	view →
GBM	OS	Quartile	All	0.324	0.206	.022	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

GO:0019856–MESO (OS)

Open the MESO breakdown →